Hodgkin lymphoma

Connors, Joseph M.; Cozen, Wendy; Steidl, Christian; Carbone, Antonino; Hoppe, Richard T.; Flechtner, Hans‐Henning; Bartlett, Nancy L.

doi:10.1038/s41572-020-0189-6

Cited by 137 publications

(163 citation statements)

References 244 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…Lymphoma is a heterogeneous cancer divided into two major types such as Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) (1,2). In oncology research, management of lymphoma stands out as the choice of treatment is largely based on the results obtained from prospective clinical trials (1). Standard treatment regimen includes chemotherapy and radiation therapy for the treatment of HL and chemotherapy combined with anti-CD20 antibodies for NHL patients, reaching the cure rate of 80-90% (1,2).…”

Section: Introductionmentioning

confidence: 99%

“…In oncology research, management of lymphoma stands out as the choice of treatment is largely based on the results obtained from prospective clinical trials (1). Standard treatment regimen includes chemotherapy and radiation therapy for the treatment of HL and chemotherapy combined with anti-CD20 antibodies for NHL patients, reaching the cure rate of 80-90% (1,2). Even though the response rate is high, treatment-related toxicity such as induction of second malignancy and cardiotoxicity is of a major concern (1).…”

Section: Introductionmentioning

confidence: 99%

“…Standard treatment regimen includes chemotherapy and radiation therapy for the treatment of HL and chemotherapy combined with anti-CD20 antibodies for NHL patients, reaching the cure rate of 80-90% (1,2). Even though the response rate is high, treatment-related toxicity such as induction of second malignancy and cardiotoxicity is of a major concern (1). Following initial treatment, 10-30% of lymphoma patients develop refractory or recurrent (r/r) disease which is treated with high-dose chemotherapy followed by an autologous hematopoietic stem cell transplantation (ASCT) (1,2).…”

Section: Introductionmentioning

confidence: 99%

“…Even though the response rate is high, treatment-related toxicity such as induction of second malignancy and cardiotoxicity is of a major concern (1). Following initial treatment, 10-30% of lymphoma patients develop refractory or recurrent (r/r) disease which is treated with high-dose chemotherapy followed by an autologous hematopoietic stem cell transplantation (ASCT) (1,2). The overall goal of current and emerging treatments for HL and NHL is to cure disease and minimize treatment-related toxicity (1,2).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Heat Shock Proteins in Lymphoma Immunotherapy

2021

View full text Add to dashboard Cite

Immunotherapy harnessing the host immune system for tumor destruction revolutionized oncology research and advanced treatment strategies for lymphoma patients. Lymphoma is a heterogeneous group of cancer, where the central roles in pathogenesis play immune evasion and dysregulation of multiple signaling pathways. Immunotherapy-based approaches such as engineered T cells (CAR T), immune checkpoint modulators and NK cell-based therapies are now in the frontline of lymphoma research. Even though emerging immunotherapies showed promising results in treating lymphoma patients, low efficacy and on-target/off-tumor toxicity are of a major concern. To address that issue it is suggested to look into the emerging role of heat shock proteins. Heat shock proteins (HSPs) showed to be highly expressed in lymphoma cells. HSPs are known for their abilities to modulate immune responses and inhibit apoptosis, which made their successful entry into cancer clinical trials. Here, we explore the role of HSPs in Hodgkin and Non-Hodgkin lymphoma and their involvement in CAR T therapy, checkpoint blockade and NK cell- based therapies. Understanding the role of HSPs in lymphoma pathogenesis and the ways how HSPs may enhance anti-tumor responses, may help in the development of more effective, specific and safe immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Heat Shock Proteins in Lymphoma Immunotherapy

2021

View full text Add to dashboard Cite

show abstract

Association of Single-Nucleotide Variants in the Human Leukocyte Antigen and Other Loci With Childhood Hodgkin Lymphoma

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEStudies focusing on genetic susceptibility of childhood Hodgkin lymphoma (HL) are limited. OBJECTIVES To identify genetic variants associated with childhood-onset HL vs adult-onset HL. DESIGN, SETTING, AND PARTICIPANTS This genetic association study was performed with 3 cohorts: the St Jude Lifetime Cohort Study (SJLIFE), initiated in 2007 with ongoing follow-up, and the original and expansion cohorts of the Childhood Cancer Survivor Study (CCSS), initiated in the 1990s with ongoing follow-up. Results of these genome-wide association studies (GWASs) were combined via meta-analysis. Data were analyzed from June 2021 to June 2022. MAIN OUTCOMES AND MEASURES Childhood HL was the focused outcome. Single-nucleotide variant (SNV, formerly single-nucleotide polymorphism) array genotyping and imputation were conducted for the CCSS original cohort, and whole-genome sequencing was performed for the SJLIFE and CCSS expansion cohort.RESULTS A total of 1286 HL cases (mean diagnosis [SD] age, 14.6 [3.9] years), 6193 non-HL childhood cancer cases, and 369 noncancer controls, all of European ancestry, were included in the analysis. Using step-wise conditional logistic regression, the odds ratios (ORs) for each of the 3 independent SNVs identified in the human leukocyte antigen (HLA) locus were 1.80 (95% CI, 1.59-2.03;

show abstract